There’s a silent revolution going on, led by a group of complex chemicals produced by one of the most controversial plants ever. Cannabis, for all the negativity that’s associated with it, produces a group of chemicals that’s sure to revolutionize the medical world in a few years. They’re called cannabinoids, and cannabis produces over 100 of them. Researchers are constantly learning new things about this group of unique compounds.
The two most prominent ones are cannabidiol and THC (delta-9 tetrahydrocannabinol), and they make up a large portion of the cannabinoids present. THC is produced in large quantities in marijuana, and it’s responsible for the psychoactive high marijuana is famous for.
Cannabidiol, on the other hand, is said to be a potent natural medicine. According to anecdotal evidence, it’s capable of acting against chronic pain, anxiety, high blood pressure and a list of other conditions. Last year, the U.S. Food and Drug Administration approved a CBD-based drug to treat seizures in two rare and hard to treat pediatric epilepsies, Dravet Syndrome and Lennox-Gastaut Syndrome.
One of the lesser-known cannabinoids is called CBC, or cannabichromene. It is non-psychoactive, structurally similar to CBD, and like all cannabinoids, interacts with the endocannabinoid system (ECS). However, unlike THC and CBD, it binds poorly with the CB1 and CB2 receptors. These are receptors spread all around the body that interact with endocannabinoids to help regulate functions such as sleep and pain.
Interest in CBC can be traced back to the eighties. In 1981, researchers studied the antibacterial, anti-inflammatory and antifungal properties of CBC. The study found that CBC’s anti-inflammatory effects were superior to phenylbutazone, an NSAID pain medication. They also found that it had strong antibacterial properties and mild to moderate antifungal properties.
A different study carried out in 2006 into the anti-tumor effects of cannabidiol, cannabigerol (CBG), CBC, cannabidiol acid and THC acid found that CBD and CBC had a pronounced negative effect against certain tumor growths in rats.
In 2010, researchers studying the effect of CBD and CBC on the descending pathway of antinociception in anesthetized rats found that both of them could help alleviate pain caused by nerve damage by preventing sensory neuron cells from detecting the pain signals.
Generally, CBC appears to have similar properties with other cannabinoids such as pain management, anti-inflammatory, anti-tumor and pathogenic disease-fighting properties. However, little is still known about CBC, and research is still going on.
One wouldn’t be far off if they assumed that established cannabidiol companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) could also be looking into how less-known cannabinoids like CBC can be beneficial to people in different walks of life.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
